MX2011006541A - Monocarbamas. - Google Patents

Monocarbamas.

Info

Publication number
MX2011006541A
MX2011006541A MX2011006541A MX2011006541A MX2011006541A MX 2011006541 A MX2011006541 A MX 2011006541A MX 2011006541 A MX2011006541 A MX 2011006541A MX 2011006541 A MX2011006541 A MX 2011006541A MX 2011006541 A MX2011006541 A MX 2011006541A
Authority
MX
Mexico
Prior art keywords
compound
compounds
pharmaceutically acceptable
formula
preparation
Prior art date
Application number
MX2011006541A
Other languages
English (en)
Spanish (es)
Inventor
Mark Edward Flanagan
Steven Joseph Brickner
Manjinder Singh Lall
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2011006541A publication Critical patent/MX2011006541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
MX2011006541A 2008-12-19 2009-12-07 Monocarbamas. MX2011006541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13915908P 2008-12-19 2008-12-19
PCT/IB2009/055544 WO2010070523A1 (en) 2008-12-19 2009-12-07 Monocarbams

Publications (1)

Publication Number Publication Date
MX2011006541A true MX2011006541A (es) 2011-07-20

Family

ID=41727494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006541A MX2011006541A (es) 2008-12-19 2009-12-07 Monocarbamas.

Country Status (15)

Country Link
US (2) US8252782B2 (enExample)
EP (1) EP2379546A1 (enExample)
JP (1) JP2012512863A (enExample)
KR (1) KR20110086742A (enExample)
CN (1) CN102325769A (enExample)
AR (1) AR074801A1 (enExample)
AU (1) AU2009329169B2 (enExample)
CA (1) CA2744756C (enExample)
IL (1) IL213216A0 (enExample)
MX (1) MX2011006541A (enExample)
PA (1) PA8855001A1 (enExample)
SG (1) SG171781A1 (enExample)
TW (1) TW201026696A (enExample)
UY (1) UY32336A (enExample)
WO (1) WO2010070523A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379546A1 (en) * 2008-12-19 2011-10-26 Pfizer Inc. Monocarbams
CA2815821C (en) * 2010-11-29 2015-07-07 Pfizer Inc. Monobactams useful for treating bacterial infections
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
HRP20201423T1 (hr) * 2015-09-23 2020-12-11 Novartis Ag Soli i čvrsti oblici antibiotika monobaktam
CN105481812B (zh) * 2015-11-30 2020-04-21 重庆天奕恒化科技有限公司 一种5-苄氧基-4-氧代-4h-吡喃-2-羧酸的制备方法
KR20190092566A (ko) 2016-12-21 2019-08-07 아이쿠리스 게엠베하 운트 코. 카게 항생제 내성 박테리아 균주에 의한 감염을 위한 아미딘 치환된 β-락탐 화합물 및 β-락타마제 억제제를 사용하는 조합 요법
AU2018311521B2 (en) 2017-08-02 2022-03-03 Novartis Ag Process for preparing 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
US11034648B2 (en) 2017-08-23 2021-06-15 Helmholtz-Zentrum Für Cystobactamide derivatives
AU2018325894B2 (en) 2017-08-31 2022-08-04 Hokko Chemical Industry Co., Ltd. 1-(N,N-disubstituted carbamoyl) 4-(substituted sulfonyl)triazolin-5-one derivatives, 4-(N,N-disubstituted carbamoyl) 1-(substituted sulfonyl)triazolin-5-one derivatives, and herbicide containing same as active ingredient
CN111511737B (zh) 2018-01-29 2022-10-18 南京明德新药研发有限公司 用于治疗细菌感染的单环β-内酰胺化合物
WO2020125670A1 (zh) 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
EP4079305A4 (en) 2019-12-19 2024-01-10 Shenzhen Optimum Biological Technology Co., Ltd APPLICATION OF A COMPOUND IN THE PREPARATION OF DRUG

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199981A (en) 1981-04-09 1985-08-16 Squibb & Sons Inc 2-oxo-1-(((substituted sulphonyl)amino)carbonyl)azetidines
US4587047A (en) * 1981-04-09 1986-05-06 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US5006650A (en) * 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
JPH02502378A (ja) 1987-02-11 1990-08-02 ジ・アップジョン・カンパニー 抗生物質としての新規なＮ‐１置換β‐ラクタム
JPH02502455A (ja) * 1987-02-27 1990-08-09 ジ・アップジョン・カンパニー ピリドンカルボン酸または酸誘導体を含有する抗生物質β‐ラクタム
CA1317298C (en) * 1987-03-03 1993-05-04 Upjohn Company (The) Antibiotic sulfonylaminocarbonyl activated .beta.-lactams
US4762922A (en) * 1987-07-01 1988-08-09 Squibb Corporation 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US5015737A (en) * 1987-07-22 1991-05-14 The Upjohn Company Therapeutically useful beta-lactams
US4777252A (en) * 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US4889930A (en) 1987-12-21 1989-12-26 E. R. Squibb & Sons, Inc. Process for making 2-oxo-1-((substituted sulfonyl)amino)carbonzyl)azetidines and intermediates used therein
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
EP0344707A3 (en) 1988-06-02 1990-04-18 E.R. Squibb & Sons, Inc. 2-Oxo-1-[[(substituted sulfonyl)-amino]carbonyl]-azetidine derivatives
US4959470A (en) * 1988-08-17 1990-09-25 E. R. Squibb & Sons, Inc. 2-oxo-[[(substituted sulfonyl)-amino]carbonyl]-azetidines
AU4064089A (en) 1988-09-27 1990-04-18 Upjohn Company, The Dihydroxyaryl 4-substituted monocarbams as antibiotics
CA2210787A1 (en) 1997-07-17 1999-01-17 William R. Collier Self-contained work station
MX2009009918A (es) 2007-03-23 2009-10-19 Basilea Pharmaceutica Ag Medicamentos combinados para el tratamiento de infecciones bacterianas.
EP2379546A1 (en) * 2008-12-19 2011-10-26 Pfizer Inc. Monocarbams

Also Published As

Publication number Publication date
UY32336A (es) 2010-07-30
US8252782B2 (en) 2012-08-28
TW201026696A (en) 2010-07-16
US8324198B1 (en) 2012-12-04
AU2009329169A1 (en) 2010-06-24
IL213216A0 (en) 2011-07-31
PA8855001A1 (es) 2010-07-27
EP2379546A1 (en) 2011-10-26
AR074801A1 (es) 2011-02-16
AU2009329169B2 (en) 2012-06-28
CN102325769A (zh) 2012-01-18
CA2744756C (en) 2013-05-28
SG171781A1 (en) 2011-07-28
JP2012512863A (ja) 2012-06-07
WO2010070523A1 (en) 2010-06-24
US20120289455A1 (en) 2012-11-15
CA2744756A1 (en) 2010-06-24
KR20110086742A (ko) 2011-07-29
US20100160281A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
US8324198B1 (en) Monocarbams
JP5677634B2 (ja) １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
JP6386132B2 (ja) １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
ES2244666T3 (es) Derivados de acidos 3-(heteroaril-acetamido)-2-oxoazetidina-1-sulfonicos utilizados como agentes antibacterianos.
JP2020536082A (ja) 細菌感染症を治療するためのクロマンモノバクタム化合物
JP4064462B2 (ja) セフェム化合物及び該化合物を含有する医薬
KR20050037973A (ko) 디펩티딜 펩티데이즈-ⅳ(ｄｐｐ-ⅳ) 저해용 신규 화합물,그것의 제조방법 및 그것을 활성성분으로서 함유하는 약제조성물
KR910000035B1 (ko) 세팔로스포린 화합물, 이의 제법 및 이를 함유하는 약학적 조성물
US20060106034A1 (en) Drug efflux pump inhibitor
JP7360132B2 (ja) オキソ置換化合物
WO2019009369A1 (ja) イミン誘導体
JPH0145473B2 (enExample)
WO2019009370A1 (ja) アミド誘導体
WO1998034936A1 (en) Carbapenem compounds, use thereof, and intermediate compounds of the same
WO1995025109A1 (en) Cephem compound, process for producing the same, and antibacterial containing the compound
EP4025577A1 (en) Siderophore cephalosporin conjugates and uses thereof
HK1161238A (en) Monocarbams
JPS60237090A (ja) セフエム化合物
GB2144126A (en) Penem carboxylix acids and the preparation thereof
US20230365551A1 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
KR810001093B1 (ko) 신규 세팔로스포린 유도체의 제조방법
JPH07304779A (ja) セフェム化合物、その製造方法及び該化合物を含む抗菌剤
JP2008521792A (ja) 抗菌薬としてのジアゼピンオキサゾリジノン
JPH05294974A (ja) セフエム化合物およびそれを含有する抗菌組成物
WO1988010263A1 (fr) Composes cristallins de cephalosporine, procede de preparation et produits intermediaires pour la preparation de ces composes

Legal Events

Date Code Title Description
FG Grant or registration